Head-to-head evidence
BAT1706 vs LY01008
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
BAT1706 · Avzivi
Marketed by Bio-Thera Solutions
NCT03329911 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled, with 651 participants, and used a clinical tumor-response endpoint assessed by RECIST 1.1. However, the week-18 primary endpoint comparison is unclear because only response counts are posted and no statistical analysis is reported.
LY01008
Developed by Luye Pharma Group
NCT03533127 · Phase 3 · status unknown
This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · LY01008's landscape